Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grace TherapeuticsGRCE +1.87%29 Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus rates GRCE with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 181 Biotechnology companies, Grace Therapeutics ranks worse than 552485.64% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Grace Therapeutics's forward rate of return for was 0.00%.
The historical rank and industry rank for Grace Therapeutics's Forward Rate of Return (Yacktman) % or its related term are showing as below:
During the past 13 years, Grace Therapeutics's highest Forward Rate of Return was 16.12. The lowest was 13.40. And the median was 16.12.
GRCE's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 1.92 * Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Grace Therapeutics (NAS:GRCE) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Grace Therapeutics Forward Rate of Return (Yacktman) % Related Terms
Grace Therapeutics Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for Grace Therapeutics's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grace Therapeutics Forward Rate of Return (Yacktman) % Chart
GRCE vs PDSB, HYPD, RNXT: Forward Rate of Return (Yacktman) % Comparison
For the Biotechnology subindustry, Grace Therapeutics's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics Forward Rate of Return (Yacktman) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's Forward Rate of Return (Yacktman) % falls into.
Grace Therapeutics Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 0.00% mean?
Grace Therapeutics (GRCE) has a Forward Rate of Return (Yacktman) % of 0.00% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Grace Therapeutics and its competitors. Over the past decade, Grace Therapeutics' Forward Rate of Return (Yacktman) % has ranged from 13.40 to 16.12. According to the industry distribution chart, Grace Therapeutics ranks #999999 out of 181 companies in the Biotechnology industry.
Is Grace Therapeutics' Forward Rate of Return (Yacktman) % too high?
Grace Therapeutics' current Forward Rate of Return (Yacktman) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 13.40 to a high of 16.12. Based on the distribution chart, Grace Therapeutics ranks #999999 out of 181 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Grace Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Forward Rate of Return (Yacktman) % compare to PDSB and HYPD?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #999999 out of 181 companies for Forward Rate of Return (Yacktman) %. This places Grace Therapeutics in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 1.92. Historically, Grace Therapeutics' own Forward Rate of Return (Yacktman) % has ranged from 13.40 to 16.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Biotechnology company?
The median Forward Rate of Return (Yacktman) % among Biotechnology companies is 1.92, based on 181 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Grace Therapeutics and its competitors. For the Biotechnology industry, the median Forward Rate of Return (Yacktman) % is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current Forward Rate of Return (Yacktman) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Forward Rate of Return (Yacktman) % of 0.00%. The current Forward Rate of Return (Yacktman) % is 0.00%. Grace Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
29GF Score
Get the complete analysis for GRCE
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 
